Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 1361-1369

  Rothman, Richard B ^a   Blough, Bruce E ^b   Woolverton, William L ^c   Anderson, Karen G ^c   Negus, S Stevens ^d   Mello, Nancy K ^d   Roth, Bryan L ^e   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d MCLEAN HOSPITAL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPTHYL 2 AMINOPROPANE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; BIOGENIC AMINE; CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE; METHAMPHETAMINE; PAL 287; SEROTONIN; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SELF ADMINISTRATION; DYSPHORIA; FRONTAL CORTEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RELAPSE; RHESUS MONKEY; WITHDRAWAL SYNDROME;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 19444387962     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.082503     Document Type: Article

References (53)

1. Alim TN, Rosse RB, Vocci FJ Jr, Lindquist T, and Deutsch SI (1995) Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: a test of the cocaine-agonist hypothesis. Clin Neuropharmacol 18:183-195.
2. Banken JA (2004) Drug abuse trends among youth in the United States. Ann NY Acad Sci 1025:465-471.
3. Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, and Rothman RB (2000) Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36:102-113.
4. Baumann MH, Ayestas MA, Dersch CM, and Rothman RB (2001) 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24:492-501.
5. Baumann MH and Rothman RB (1998) Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol Psychiatry 44:578-591.
6. Bendotti C, Borsini F, Zanini MG, Samanin R, and Garattini S (1980) Effect of fenfluramine and norfenfluramine stereoisomers on stimulant effects of d-amphetamine and apomorphine in the rat. Pharmacol Res Commun 12:567-574.
7. Bockaert J, Brand C, and Journot L (1997) Do recombinant receptor assays provide affinity and potency estimates? Ann NY Acad Sci 812:55-70.
8. Burmeister JJ, Lungren EM, Kirschner KF, and Neisewander JL (2004) Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 29:660-668.
9. Carroll ME, Lac ST, Asencio M, and Kragh R (1990) Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 35:237-244.
10. Czoty PW, Ginsburg BC, and Howell LL (2002) Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300:831-837.
11. Dackis CA and Gold MS (1985) New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 9:469-477.
12. Daw ND, Kakade S, and Dayan P (2002) Opponent interactions between serotonin and dopamine. Neural Netw 15:603-616.
13. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
14. Garlow SJ, Purselle D, and D'Orio B (2003) Cocaine use disorders and suicidal ideation. Drug Alcohol Depend 70:101-104.
15. Gawin FH and Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 43:107-113.
16. Glatz AC, Ehrlich M, Bae RS, Clarke MJ, Quinlan PA, Brown EC, Rada P, and Hoebel BG (2002) Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Pharmacol Biochem Behav 71:197-204.
17. Glowa JR, Rice KC, Matecka D, and Rothman RB (1997) Phentermine/ fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 8:1347-1351.
18. Gorelick DA (1998) The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 42:995-997.
19. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, and Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522-526.
20. Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller FG, Hassan S, and Schmitz J (2004) Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29:969-981.
21. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, and Korszun A (1997) Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 17:485-488.
22. Henningfield JE (1995) Nicotine medications for smoking cessation. N Engl J Med 333:1196-1203.
23. Howell LL and Byrd LD (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275:1551-1559.
24. Kampman KM, Rukstalis M, Pettinati H, Muller E, Acosta T, Gariti P, Ehrman R, and O'Brien CP (2000) The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. J Subst Abuse Treat 19:77-79.
25. Katz JL and Higgins ST (2003) The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl) 168:21-30.
26. Kreek MJ (1996) Opiates, opioids and addiction. Mol Psychiatry 1:232-254.
27. Kresina TF, Normand J, Khalsa J, Mitty J, Flanigan T, and Francis H (2004) Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities. Clin Infect Dis 38 (Suppl 5):S398-S401.
28. Mann JJ (2003) Neurobiology of suicidal behaviour. Nat Rev Neurosci 4:819-828.
29. Negus SS and Mello NK (2002) Effects of n-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of μ-agonist efficacy. J Pharmacol Exp Ther 300:1111-1121.
30. Negus SS and Mello NK (2003a) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Bert) 167:324-332.
31. Negus SS and Mello NK (2003b) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70:39-52.
32. Rea WP, Rothman RB, and Shippenberg TS (1998) Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: concordance with clinical studies. Synapse 30:107-111.
33. Roberts DC, Phelan R, Hodges LM, Hodges MM, Bennett B, Childers S, and Davies H (1999) Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) 144:389-397.
34. Rothman RB and Baumann M (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88.
35. Rothman RB and Baumann MH (2000) Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects. Drug Dev Res 51:52-65.
36. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
37. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
38. Rothman RB, Blough BE, and Baumann MH (2002a) Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann NY Acad Sci 965:109-126.
39. Rothman RB, Gendron TM, and Hitzig P (1994) Combined use of fenfluramine and phentermine in the treatment of cocaine addiction: a pilot case series. J Subst Abuse Treat 11:273-275.
40. Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, and Baumann MH (2002b) Interaction of the anorectic medication, phendimetrazine and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447:51-57.
41. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229.
42. Shearer J and Cowing LR (2004) Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 23:203-211.
43. Shearer J, Wodak A, van Seek I, Mattick RP, and Lewis J (2003) Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98:1137-1141.
44. Smith FL, Yu DS, Smith DG, Leccese AP, and Lyness WH (1986) Dietary tryptophan supplements attenuate amphetamine self-administration in the rat. Pharmacol Biochem Behav 25:849-855.
45. van den Brink W and van Ree JM (2003) Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13:476-487.
46. Vickers SP, Clifton PG, Dourish CT, and Tecott LH (1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HTE(2C) receptor mutant mice. Psychopharmacology 143:309-314.
47. Walsh SL and Cunningham KA (1997) Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 130:41-58.
48. Walsh SL, Haberny KA, and Bigelow GE (2000) Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150:361-373.
49. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854.
50. Wee S, Ordway GA, and Woolverton WL (2004) Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol 493:117-125.
51. Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6:243-251.
52. Wojnicki FHE, Rothman RB, Rice KC, and Glowa JR (1999) Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food-presentation and cocaine-delivery in the rhesus monkey. J Pharmacol Exp Ther 288:550-560.
53. Woods JH and Tessel RE (1974) Fenfluramine: amphetamine congener that fails to maintain drug-taking behavior in the rhesus monkey. Science (Wash DC) 185:1067-1069.